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Abstract Krüppel-like zinc-finger transcription factor 5
(KLF5), known as BTEB2 or IKLF, has several biological
functions that involve cell proliferation, development and apo-
ptosis. Previous studies demonstrated that BTEB2 had anti-
apoptotic effect in multiple diseases such as esophageal cancer
and non-small cell lung cancers (NSCLCs). However, the
distribution and function of BTEB2 in CNS diseases remain
unknown. In this study, we show that BTEB2 down-regulates
neuronal apoptosis during pathophysiological processes of in-
tracerebral hemorrhage (ICH). A rat ICH model was
established by behavioral tests. Western blot and immunohis-
tochemistry revealed a remarkable up-regulation of BTEB2
expression surrounding the hematoma after ICH. Double-
labeled immunofluorescence showed BTEB2 was mostly co-
localized with neurons, rarely with activated astrocytes and
microglia. Furthermore, we detected that neuronal apoptosis
marker active caspase-3 had co-localizations with BTEB2. In
addition, KLF5 knockdown in vitro specifically resulted in
increasing neuronal apoptosis coupled with reduced Bad phos-
phorylation at both ser112 and ser136 residues. All our findings
suggested that BTEB2 down-regulated neuronal apoptosis via
promoting Bad phosphorylation after ICH.
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Introduction
Intracerebral hemorrhage (ICH) occurs when a diseased blood
vessel ruptures, allowing blood to leak into the surrounding
brain (Rui et al. 2013). Spontaneous ICH accounts for a signif-
icant proportion of all strokes and is one of the leading causes of
stroke related mortality and morbidity worldwide (Sun et al.
2013). Although a lot of resources have been thrown into
clinical and basic research regarding ICH, the prognosis of
patients is still very poor. It is an urgent work to improve the
clinical outcome of ICH, investigation into the pathogenesis of
ICH-induced brain injury. The primary and secondary damage
both contribute to the pathological processes following ICH
(Aronowski and Zhao 2011). Apart from the primary damage
caused by the mass effect due to hematoma formation, subse-
quent parallel pathological pathways all lead to the secondary
damage. Cytotoxicity of blood, oxidative stress and neuronal
apoptosis are the most crucial event consists of perplexing pro-
apoptotic activations and subtle anti-apoptotic accommodation.
Classical apoptosis is usually initiated by two main pathways:
the intrinsic and the extrinsic pathways (Aronowski and Zhao
2011). The activation of extrinsic pathway is triggered by
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ligands bindingwith their respective death receptors. Caspase-3
has also been proved to be a frequently activated death protease
in mammalian cell apoptosis (Gong et al. 2001).
Krüppel-like zinc-finger transcription factor 5 (KLF5), also
named BTEB2 or IKLF, belongs to the KLF family (Taniguchi
Ishikawa et al. 2013). Members of this family are made up of
over 20 identified members. They are characterized by
possessing a highly conserved C-terminal and three zinc finger
DNA-binding domains that bind to GC-rich sequences (Dang
et al. 2002; Philipsen and Suske 1999; Shi et al. 1999; Turner
and Crossley 1999). Human KLF5 is a member of the mam-
malian Krüppel-like transcription factors, found to be dynam-
ically regulated at the transcription level in mouse (Shi et al.
1999). KLF5 is widely expressed at varying levels in different
tissues such as colon, small intestine (Chen et al. 2002;
Conkright et al. 1999; Shi et al. 1999). KLF5 has recently
attracted attention because of its important regulatory activities
related to diverse functions such as cell growth, proliferation
and tumorigenesis (Suzuki et al. 2007). As a basic transcription
factor, KLF5 regulates a good number of important target genes
associated with cell cycle such as cyclinD1, cyclinB, PDGFα
and FGF-BP. KLF5 also has essential roles in cell apoptosis,
migration and differentiation (Zhao et al. 2008). Mechanical
induction of KLF5 can result in direct transactivation of
cyclinD1 expression, which subsequently stimulates cell pro-
liferation (Suzuki et al. 2009). Furthermore, KLF5 attenuates
cleaved caspase-3 expression under conditions of apoptotic
stimulation. KLF5 functions to mediate vascular remodeling
via direct and specific stimulation of cell growth and by
inhibiting apoptosis (Nakajima et al. 2012). Y Zhao and his
colleagues found that KLF5 suppressed p53-independent apo-
ptosis through Pim1 survival kinase in HCT116 p53−/−cells
(Zhao et al. 2008). Recent data have shown that apoptosis can
be controlled bymultiple of survival pathways, which converge
to promote Bad phosphorylation (Bergmann 2002). The par-
ticipation of BTEB2 in various cellular activities such as apo-
ptosis and proliferation has drawn increasingly attention (Dong
and Chen 2009; Tarapore et al. 2013; Courboulin et al. 2011).
However, our understanding of the specific roles of BTEB2 in
adult brain after ICH remains unclear.
In this report, we show that BTEB2 attenuates neuronal
apoptosis following ICH by in vivo and in vitro experiments.
We for the first time investigated the expression and distribu-
tion of BTEB2 in rat caudate putamen around the hematoma
after ICH.
Materials and Methods
Animals and the ICH Model
All animal care and surgical interventions were implemented
according to the National Institutes of Health Guidelines for
the Care and Use of Laboratory Animals (National Research
Council 1996, USA); all animal procedures were acknowl-
edged by the Department of Animal Center, Medical College
of Nantong University. Male Sprague–Dawley rats with an
average weight of 250 g were used. The rats were anesthetized
intraperitoneally with sodium pentobarbital (50 mg/kg) and
then positioned in a stereotaxic frame. A cranial burr hole was
drilled near the right coronal suture 3.5 mm lateral to the
midline (Sun et al. 2013). Autologous whole blood (50 μl)
was collected in a sterile syringe by cutting the tail tip (Xue
and Del Bigio 2003). The sterile syringe was inserted stereo-
taxically into the right caudate putamen (coordinates: 0.2 mm
anterior, 5.5 mm ventral, 3.5 mm lateral to the bregma) (Xue
and Del Bigio 2003). The sham group only had a needle
insertion. The needle was removed 10 min after injection,
the skin incision closed and the animals were allowed to
recover. Experimental animals (n=6–8 per time point) were
killed to extract the protein for Western blot analysis at 6 h,
12 h, 1 day, 2 days, 3 days, 5 days, 7 days and 9 days after
ICH. Rats in the sham group (n=3) were sacrificed on the
third day. An additional two rats at each time point from the
experimental group were killed for pathologic studies. All
efforts were made to minimize the number of animals used
and their suffering.
Exclusions and Mortality
Three animals in Western blot, five in immunohistochemistry
and four in immunofluorescent were excluded due to technical
difficulties, experimenter error and mortality. Mortality oc-
curred only after the operation error to cause severe ICH. In
total, seven animals had a severe ICH, four of which died
within 24 h (p=0.215 vs. SHAM).Three died quickly after
ICH. After exclusions, 12 rats remained (ICH: n=6, SHAM:
n=6), immunohistochemistry had ten rats (ICH: n=6, SHAM:
n=4) and immunofluorescent had 16 rats (ICH: n=8, SHAM:
n=8).
Cell Cultures and Stimulation
PC12 cells were cultured in Dulbecco’s modified medium
with 10 % (v/v) fetal bovine serum, 5 % donor horse serum
and antibiotics at 37 °C under 5 % CO2 in humidified air. The
cells were passed every 3–4 days. To study apoptosis, cells
were seeded onto a poly-L-lysine-coated 60-mm dishes and
incubated in a low concentration of serum (1 % horse serum)
for 24 h prior to treatment with hemin in 100 μmol/l at
different time points.
Forelimb Placing Test
Held the rats by torsos, thus the forelimb could hang free.
Independent testing of each forelimb was elicited by brushing
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the respective vibrissae on the corner edge of a countertop.
Intact rats lay up the forelimb quickly onto the countertop.
According to the extent of injury, placing of the forelimb
contralateral to the injury may be impaired. During the exper-
iments, each rat was tested ten times for each forelimb and the
percentage of trials in which the rat placed the left forelimb
was calculated (Karabiyikoglu et al. 2004).
Corner Turn Test
The rats were allowed to proceed into a corner, the angle of
which was 30°. To exit the corner, the rat should turn either to
the left or to the right. Only the turns involving full rearing
along either wall was included (a total of eight per animal).
According to the extent of injury, rats may show a ten-
dency to turn to the side of the injury. The percentage of
right turns was used as the corner turn score. The rats
were not picked up instantly after each turn so that they
would not develop an aversion for their prepotent turning
response (Hua et al. 2002).
Western Blot Analysis
Rats were sacrificed at different time points after operation
once given an overdose of chloral hydrate. The caudate puta-
men tissues surrounding the hematoma (2 mm from the inci-
sion) and the equal part of the contralateral or sham group
were excised and instantly frozen at −80 °C until use. To
prepare lysates, frozen brain tissue samples were minced with
eye scissors in ice. The samples were then homogenized in
lysis buffer (1 % NP-40, 50 mmol/l Tris, pH=7.5, 5 mmol/l
EDTA, 1 % SDS, 1 % sodium deoxycholate, 1 % Triton
X-100, 1 mmol/l PMSF, 101 g/ml aprotinin, 11 g/ml
leupeptin) and clarified by centrifuging for 20 min in a
microcentrifuge at 4 °C. After the determination of concen-
tration with the Bradford assay (Bio-Rad), the samples were
subjected to SDS-polyacrylamide gel electrophoresis and
transferred to a polyvinylidene diflouride (PVDF) filter mem-
brane by a transfer apparatus at 350 mA for 2 h. The mem-
brane was then blocked with 5 % nonfat milk and incubated
with primary antibody against BTEB2 (anti-rabbit, 1:1,000;
Santa Cruz), active caspase-3 (anti-mouse, 1:1,000; Cell
Signaling), GAPDH (anti-rabbit, 1:1,000; Sigma) at 4 °C
overnight. Lastly, the membrane was incubated with a second
antibody for 2 h and visualized using an enhanced chemilu-
minescence system (Pierce Company, USA).
Sections and Immunohistochemistry
After determined survival time points, the rats were deeply
anesthetizedwith chloral hydrate (10% solution) and perfused
pericardially with 500 ml 0.9 % saline followed by 4 %
paraformaldehyde. After perfusion, the brains were removed
and post-fixed in the same fixative for 3 h and then replaced
with 20 % sucrose for 2–3 days, followed by 30% sucrose for
2–3 days. The tissues were embedded in OCT compound
when needed. Then, 6–7 μm frozen cross-sections were pre-
pared and examined. All sections were stored at −20 °C before
use. After the sections had been prepared, they were kept in an
oven at 37 °C for 30 min and rinsed twice in 0.01 M PBS
(pH 7.2) for 5 min. Then the sections were blocked with
confining liquid consisting of 10 % donkey serum, 1 %
BSA, 0.3 % Triton X-100 and 0.15 % Tween-20 for 2 h at
room temperature, then incubated with anti-BTEB2 anti-
body (Rabbit, 1:100, Santa Cruz) overnight at 4 °C,
followed by incubation in biotinylated secondary antibody
(Vector Laboratories, Burlingame, CA, USA). Staining was
visualized with DAB (Vector Laboratories). After reactions,
the sections were dehydrated, cleared and coverslipped. We
examined the sections and counted the cells with strong or
moderate brown staining, weak or no staining as positive or
negative BTEB2 cells respectively from each group at higher
magnification with a Leica light microscope (Leica, DM
5000B; Germany).
Fig. 1 Assessments and scores of behavioral tests on rats after ICH.
Behavioral tests were implemented in rats after ICH or sham operation.
Forelimb placing test (a) and Corner turn test (b) scores at different
survival times after ICH. The ICH group showed distinctly deficits
compared with the sham group over the first 3 days (*p<0.05) with no
significant difference at baseline or 3 days later
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Double Immunofluorescent Staining
For double immunofluorescent labeling, sections were pre-
pared as previouslymentioned. After air-dried for 1 h, sections
were first blocked with solution containing 10 % normal
serum (same species as the secondary antibody), 3 % (w/v)
BSA, 0.1 % Triton X-100 and 0.05 % Tween-20 for 2 h at
room temperature. Then the slides were incubated overnight
with primary antibody anti-BTEB2 (rabbit, 1:100; Abcam)
and different markers as follows: NeuN (mouse; 1:100;
Chemicon), GFAP (mouse; 1:100; Sigma), CD11b (mouse;
1:50; Serotec), active caspase-3 (mouse or rabbit; 1:200; Santa
Cruz), at 4 °C. In brief, sections were incubated with both
primary antibodies overnight at 4 °C and a mixture of FITC-
and TRITC-conjugated secondary antibodies (Jackson
ImmunoResearch) for 2 h at 4 °C. In order to detect the
morphology of the nucleus, sections were covered with
DAPI (0.1 mg/ml in PBS; Sigma) for 1 h at 30 °C. The stained
sections were examined with a Leica fluorescence microscope
(Leica, DM 5000B; Germany).
Quantitative Analysis
Cells double labeled for BTEB2 and cell phenotypic markers
used in the experiment were quantified. Sections were double
labeled with NeuN, GFAP, CD11b and active caspase-3. To
identify the ratio of each phenotype-specific marker-positive
cells expressing BTEB2, at least 200 phenotype-specific
marker-positive cells were counted 3 mm surrounding the
hematoma in each section. Then, double-labeled cells for
BTEB2 and phenotype-specific markers were recorded. A
total of three adjacent sections per animal were sampled.
BTEB2 siRNA and Transfection
Double-stranded siRNA of 19 nucleotides were synthesized
by Genechem. The targeting sequence of rat BTEB2 mRNA
(5′-gccccggttaatttgcatat-3′, 5′-cccagtatcagcagaaggacat-3′),
corresponds to the region 2676–2695, 3104–3125, respective-
ly, relative to the first nucleotide of the start codon (GenBank
Accession No. NM_001730). Non-silencing control siRNA is
Fig. 2 BTEB2 protein
expression following ICH.
Western blot was performed to
study the protein level of BTEB2
surrounding the hematoma at
different survival times (a).
Quantification graphs of the
intensity of staining of BTEB2
to GAPDH at each time point (b).
Data are presented as
mean ± SEM (n=3, *p<0.05)
J Mol Neurosci (2015) 55:206–216 209
an irrelevant siRNA with random nucleotides and no known
specificity. Transfection of PC12 cells with siRNA was
performed using lipofectamine 2000 reagents (Invitrogen)
according to the manufacturer’s instructions. For mock
transfection, all procedures listed above were performed
in the absence of siRNA. For transient transfection, the
BTEB2 expression vector, the non-specific vector were carried
out using lipofectamine 2000 (Invitrogen) and plus reagent in
OptiMEM (Invitrogen) as suggested by the manufacturer.
Transfected cells were used for the subsequent experiments
48 h after transfection.
Statistical Analysis
All data were analyzed with Stata 7.0 statistics software.
Values were expressed as mean ± SEM. The statistical signif-
icance of differences between groups was determined by one-




surrounding the hematoma. In the
sham group, BTEB2 was low
(a, b). At 2 days after ICH,
comparison of BTEB2 between
contralateral (c, d) and ipsilateral
brain caudate putamen (e, f),
many cells around the hematoma
showed BTEB2, the positively
stained intensity (e, f). No
positive signals were found in the
negative control (g). The number
of BTEB2 cells was largely
increased comparing the
ipsilateral group with the sham
and contralateral groups (h).
*p<0.05. Scale bar: left column,
50 μm; right columns, 10 μm
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multiple comparison tests. A p value <0.05 was considered
statistically significant. Each experiment consisted of at least
three replicates per condition.
Results
Rat ICH Model Was Established by Behavioral Tests
Rats in the sham and ICH groups were underwent forelimb
placing and corner turn test at different survival time points,
respectively. The ICH group was distinctly worse impaired
than the sham group in the first 5 days after ICH (*p<0.05).
By 7 days and thereafter, however, all rats returned to normal
behavioral levels (Fig. 1a, b).
BTEB2 Protein Expression After ICH
To quantify BTEB2 expression profile after ICH, we measured
the BTEB2 protein expression using Western blot analysis at
different time points. The BTEB2 protein level was relatively
low in the sham group, whereas it increased at 6 h after ICH,
reached the peak at day 2, then gradually decreased in the
perihematomal region (Fig. 2a, b). On the other hand, we also
detected BTEB2 protein expression in the contralateral brain,
but failed to find any significant fluctuations (data not shown).
The above data indicated that BTEB2 protein level had a
temporal change caused by ICH, suggesting that BTEB2
maybe played a role during ICH pathological process.
Expression and Distribution of BTEB2
by Immunohistochemistry
To determine the distribution of BTEB2 in brain after ICH, we
carried out immunohistochemistry on transverse cryosections
of brains. BTEB2 expression dramatically increased in the
brain tissue surrounding the hematoma at day 2 after ICH
(Fig. 3e, f, h). In the sham and contralateral brains, BTEB2
expression was weak (Fig. 3a, b, c, d). No staining signal was
observed in the negative control (Fig. 3g). These results
implied that the temporal pattern of BTEB2 after ICH was
consistent with the results of Western blot.
BTEB2 Co-localized with Neurons After ICH
In order to further study BTEB2 cellular localization in the
brain after ICH, double labeling immunofluorescent was per-
formed in transverse cryosections of brain tissues with cell-
specific markers: NeuN (amarker of neuron), GFAP (amarker
of astrocyte), CD11b (a marker of microglia), to distinguish
different cell type. According to the above Western blot and
immunohistochemistry results, the sham and ipsilateral rat
brain tissues at 2 days after ICH were selected for detection.
We found that BTEB2 co-located with neurons in the
cytoplasma and nucleus (Fig. 4a–e). Besides, the positive
signals in the peri-ICH region were more than those in the
sham group. However, no significant changes of BTEB2
expression were observed in astrocytes, and microglia be-
tween sham and ICH group (Fig. 4f–o). We also performed
the DAPI labeling and detected the nuclear condensation in
neurons at day 2 after ICH (Fig. 4c, h, m).
To understand the ratio of neurons expressing BTEB2, cell
counting was performed between ICH 2 day group and the
sham group. After ICH, BTEB2 expression significantly in-
creased merely in neurons, compared with that of the sham
group (Fig. 4p). These results showed that BTEB2 localized in
the neuronal cytoplasm and nucleus.
BTEB2 Associated with Neuronal Apoptosis After ICH
Previous studies have provided the evidence for neuronal
apoptosis surrounding the hematoma after ICH (Gong et al.
2001) and also showed that BTEB2 associated with cell
apoptosis (Dong et al. 2013). Thus, Western blot was used
to detect active caspase-3 protein expression and immunoflu-
orescent was applied to test its co-localizations with BTEB2.
The active-caspase-3 protein expression was steady before
day 2 after ICH, then increased and peaked at day 3
(Fig. 5a, b), showing opposite tendency of BTEB2 protein
expression. In other words, there was negative correlation
between BTEB2 protein expression and active caspase-3 pro-
tein expression after ICH (Figs. 2a, b and 5c). Furthermore,
the colocalizations of BTEB2/active caspase-3 in addition to
active caspase-3/NeuN (Fig. 5d–o) indicated BTEB2 might
participate in neuronal apoptosis after ICH.
BTEB2 Regulates Neuronal Apoptosis and Bad
Phosphorylation In Vitro
To identify the exact role of BTEB2 in neuronal apoptosis
after ICH, BTEB2 siRNA was employed to knockdown
Fig. 4 Double immunofluorescence staining for BTEB2 with different
phenotype-specific markers in brain caudate putamen surrounding the
hematoma. In the adult rat caudate within 3-mm distance from the
hematoma at the second day after ICH, horizontal sections were labeled
with BTEB2 (red a, f, k), different cell markers (green b, g, l) such as
neuronal marker (NeuN), microglia marker (CD11b) and astrocyte
marker (GFAP) and as well as DAPI (blue c, h, m) to show the
nucleus. The yellow and white color visualized in the merged images
represents the colocalization of BTEB2 with different phenotype-specific
markers (d, e) and the purple indicates the colocalization of the nucleus
with phenotype-specific markers (d, e, i, j, n, o). Colocalization of
BTEB2 with different phenotype-specific markers in the sham group
(e, j, o) are shown in the caudate. Quantitative analysis of NeuN-positive
cells expressed BTEB2 (%) in the sham group and 2 days after ICH. (ipsi)
indicates the perihematomal region and (sham) presents the sham group.
*Significant difference at p<0.05 compared with the sham group (p).
Error bars represent SEM. Scale bars, 20 μm (a)
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BTEB2 protein expression in PC12 cells in vitro. BTEB2
siRNA markedly knocked down BTEB2 protein expression
(Fig. 6a, b). The knockdown of BTEB2 can increase active
caspase-3 expression and also specifically resulted in reduced
Bad phosphorylation at both ser112 and ser136 residues with
or without hemin stimulation (Fig. 6c, d). Furthermore, cell
immunofluorescent staining displayed the co-localization of
BTEB2 and active caspase-3 in PC12 cells (Fig. 6e).These
experiments demonstrated that BTEB2 restrain neuronal apo-
ptosis through Bad phosphorylation pathway.
Discussion
ICH is a common fatal stroke which kills about 400,000 people
annually in China. Even if the patient survives the disease, the
resulting hematoma within brain parenchyma causing a series of
adverse events triggers secondary insults and severe neurological
deficits (Aronowski and Zhao 2011). The present study built an
ICH rat model to imitate clinical ICH by performed a controlled
autologous blood injection ICH model in adult rats. Our ICH
model rats showed obvious behavioral performance deficits.
BTEB2 was rapidly up-regulated in the perihematomal region
after ICH. Double label immunofluorescence suggested that
BTEB2 mostly co-located with neurons, but few astrocytes or
microglia. Furthermore, there was a concomitant up-regulation
of active caspase-3 with that of BTEB2 in a time-dependent
manner. In vitro, knockdown of BTEB2 promoted neuronal
apoptosis via inhibiting Bad phosphorylation. In conclusion,
BTEB2 down-regulates neuronal apoptosis via enhancing Bad
phosphorylation after ICH.
Except for the primary damage, ICH lead to series of unfa-
vorable events, which cause following secondary damage and
finally give rise to serious neurological deficits or even death
(Aronowski and Zhao 2011). Neuronal apoptosis, astrocytic
proliferation and oligodendrocytic death all occurred in these
processes. Among them, neuronal apoptosis is the most severe
consequence after ICH (Sun et al. 2013). Apoptosis, also known
as programmed cell death, includes both extrinsic and intrinsic
pathways. There are some overlaps between the two pathways
and they both activate caspase-3 in the end. Caspase-3 activation
involved neuronal apoptosis after ICH. Active caspase-3 expres-
sion is remarkably increased after ICH (Rui et al. 2013). The
secondary injury following ICH comprises both anti-apoptotic
and pro-apoptotic signaling cascades. Pro-apoptotic agents in-
cluding p53, Bax and caspase-3 are increased in rat ICH models
(Ke et al. 2013). BTEB2 expression increase in neurons in our
study suggests that BTEB2 may play a role during neuronal
apoptosis after ICH. Our result showed that active caspase-3 was
up-regulated after injection, peaked at day 3. Not surprisingly,
active caspase-3 expression showed opposite tendency to that of
BTEB2, indicating that BTEB2 may downregulate neuronal
apoptosis after ICH.
The role of Bad in apoptotic control is undisputed (Chao and
Korsmeyer 1998). More importantly, the control of Bad activity
appears to be at the junction where various signal transduction
pathways are coupled to apoptosis (Horne et al. 2014). When
unphosphorylated, active Bad induces apoptosis by sequestering
anti-apoptotic members of the Bcl2 family (e.g., Bcl2 and
BclXL), permitting aggregation of pro-apoptotic members (e.g.,
Bax and Bak) (Ruvolo et al. 2001). The latter then drives
cytochrome C release and caspase activation. The apoptotic
phenotype consequent to damage is associated with reduced
Bad phosphorylation, and down-regulation of Pim1. Pim1 be-
longs to a family of survival kinases that function downstream of
JAK/STAT activation and regulates both cellular apoptosis and
metabolism. BTEB2 modulates the apoptotic response in a p53-
independent manner and suggest an association between BTEB2
and Bad phosphorylation (Zhao et al. 2008). Pim1 phosphory-
lates a range of cellular substrates, which includes Bad at two
distinct residues: ser112 and ser136 (Aho et al. 2004;Macdonald
et al. 2006; Porter and Janicke 1999). Recent data have shown
that cell apoptosis can be controlled by a number of survival
pathways, which converge to facilitate Bad phosphorylation
(Bergmann 2002). This possibility made us to question if
BTEB2 functions in the same pathway in PC12 cells. In our
studies, active caspase-3 and Bad phosphorylation apparently
increase and decrease respectively in PC12 cells hemin induced
apoptosis model. As the key factor during execution phase of
apoptosis, caspase-3 converge signals from both the intrinsic and
extrinsic pathways (Porter and Janicke 1999). Hereby, we spec-
ulate that BTEB2 inhibits neuronal apoptosis through Bad phos-
phorylation pathway after ICH.
BTEB2 regulates both apoptosis in the early phase and
proliferation in the late phase, thus indicating that this factor
acts as a bimodal and likely central regulator of proliferative
cardiovascular pathologies (Suzuki et al. 2009). BTEB2 in
some processes are generally mediated by direct transcription-
al regulation of its target genes and may have both
transactivating and repressive functions. BTEB2 activates
the JNK pathway causing apoptosis and reduced cell survival
in esophageal squamous cell cancer cells. Transcriptional
control of many steps in the JNK pathway by KLF5 is char-
acteristic of a coherent feed-forward loop and is indicative of
the critical role of KLF5 in the regulation of this signaling
Fig. 5 Association of BTEB2 with neuronal expressed active caspase-3
after ICH. The expression of active caspase-3 increased and peaked at day
3 after ICH, GAPDH was used to confirm that equal amount of protein
was run on gel (a).Quantification graphs (relative optical density) of the
intensity of staining of active caspase-3 and GAPDH at each time points
(b). Negative correlation between BTEB2 protein expression and active
caspase-3 protein expression after ICH (c). The data are mean ± SEM
(p<0.05, asterisk [*] indicates statistical significance from the sham
group). Sections labeled with active caspase-3 (d, g, j, m), NeuN (e, h),
BTEB2 (k, n), and the co-localization of active caspase-3/NeuN and
active caspase-3/BTEB2 surrounding the hematoma at day 2 after ICH
(f, i, l, o). Scale bars, 20 μm (d–o)
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Fig. 6 BTEB2 prevents neuronal
apoptosis through Bad
phosphorylation. Western blot
showed siRNA knocked down
BTEB2 expression in PC12 cells
(a). Knocking down BTEB2
induced increasing levels of
active caspase-3 and reduced the
levels of P-ser112-bad and
P-ser136-bad in hemin-treated
PC12 cells (c). The bar chart
indicates the density of active
caspase-3/BTEB2/P-ser112-Bad/
P-ser136-Bad versus GAPDH
(b, d). Data are presented as
means ± SEM (*p<0.05,
#p<0.05). Immunofluorescence
showed the co-localization of
BTEB2/active-caspase-3 in
control and non-specific siRNA
or BTEB2 siRNA transfected
PC12 cells after hemin stimulus;
meanwhile, the phenotype
changes of nuclei were also
investigated via DAPI staining (e)
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network (Tarapore et al. 2013). The molecular mechanism that
BTEB2 regulates apoptosis remains to be explored.
Taken together, our data suggest that BTEB2 prevents
neuronal apoptosis after ICH via Bad phosphorylation path-
way. Further studies are warranted to inquire the therapeutic
potentials of BTEB2 for ICH as well as ischemic stroke and
other neurodegenerative diseases.
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